Dexcom (DXCM) FY2025 10-K Annual Report
Dexcom (DXCM) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 12, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Dexcom FY2025 10-K Analysis
Business Overview
- • Core business: Design, development, and commercialization of continuous glucose monitoring (CGM) systems for diabetes and metabolic health management
- • New product launched: Stelo, first over-the-counter glucose biosensor for prediabetes and Type 2 diabetes adults not using insulin (U.S. launch Aug 2024)
- • Strategic shift: Expanded market beyond insulin-using diabetics to prediabetes and broader metabolic health with OTC Stelo product
- • Quantitative metric: G7 15 Day system FDA cleared with 15.5-day wear, 8.0% MARD accuracy, coverage by Medicare and Medicaid in majority of U.S. states
- • Noteworthy fact: Dexcom ONE+ CGM system received CE Mark approval Nov 2023 and launched in multiple European countries, expanding international presence
Management Discussion & Analysis
- • Revenue $4,662M, up 16% YoY from $4,033M driven by 600K-700K net customer additions
- • Operating margin 20.0% vs 14.9%, operating income $911.8M up 52% YoY from $600.0M
- • Best segment: U.S. distributor revenue $3,195.7M up $371.3M; worst segment: U.S. direct revenue $139.2M up $73.8M (smallest absolute growth)
- • Net income $836.3M up 45% YoY with net margin 17.9% vs 14.3%
- • Cash from operations supporting R&D ($599.1M), SG&A ($1,291M), no specific buybacks/dividends noted; expectations of adequate liquidity, possible future debt market access for inorganic growth
Risk Factors
- • Cybersecurity risk exposure due to integration of cloud-based technology platforms increasing operational costs
- • Board Technology Committee delegation for cybersecurity risk oversight with annual compliance reviews to applicable laws and standards
- • Key-person dependency on cybersecurity officers with 15-25 years experience and multiple professional certifications managing risk
- • Supply chain vulnerability linked to global IT infrastructure managed by CIO with 30 years experience in IT and supply chain
- • No specific regulatory, geopolitical, competitive, or financial risk detailed in this section
Dexcom FY2025 Key Financial MetricsXBRL
Revenue
$4.7B
▲ +15.6% YoY
Net Income
$836M
▲ +45.1% YoY
Gross Margin
60.1%
▼ -36bp YoY
Operating Margin
19.6%
▲ +468bp YoY
Net Margin
17.9%
▲ +365bp YoY
ROE
30.5%
▲ +305bp YoY
Total Assets
$6.3B
▼ -2.2% YoY
EPS (Diluted)
$2.09
▲ +47.2% YoY
Operating Cash Flow
$1.4B
▲ +45.6% YoY
Source: XBRL data from Dexcom FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Dexcom
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.